Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy

Página do item simplificado
dc.contributor.authorZavascki, Alexandre P.
dc.contributor.authorCarvalhaes, Cecilia G. [UNIFESP]
dc.contributor.authorPicao, Renata C. [UNIFESP]
dc.contributor.authorGales, Ana C. [UNIFESP]
dc.contributor.institutionHosp Clin Porto Alegre
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.date.accessioned2016-01-24T13:59:10Z
dc.date.available2016-01-24T13:59:10Z
dc.date.issued2010-01-01
dc.description.abstractPseudomonas aeruginosa and Acinetobacter baumannii are major nosocomial pathogens worldwide. Both are intrinsically resistant to many drugs and are able to become resistant to virtually any antimicrobial agent. An increasing prevalence of infections caused by multidrug-resistant (MDR) isolates has been reported in many countries. the resistance mechanisms of P. aeruginosa and A. baumannii include the production of beta-lactamases, efflux pumps, and target-site or outer membrane modifications. Resistance to multiple drugs is usually the result of the combination of different mechanisms in a single isolate or the action of a single potent resistance mechanism. There are many challenges in the treatment of MDR P. aeruginosa and A. baurnannii, especially considering the absence of new antimicrobials in the drug-development pipeline. in this review, we present the major resistance mechanisms of P. aeruginosa and A. baumannii, and discuss how they can affect antimicrobial therapy, considering recent clinical, microbiological, pharmacokinetic and pharmacodynamic findings of the main drugs used to treat MDR isolates.en
dc.description.affiliationHosp Clin Porto Alegre, Infect Dis Unit, BR-90035903 Porto Alegre, RS, Brazil
dc.description.affiliationUniversidade Federal de São Paulo, Lab ALERTA, BR-04039032 São Paulo, Brazil
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Lab ALERTA, BR-04039032 São Paulo, Brazil
dc.description.sourceWeb of Science
dc.description.sponsorshipConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
dc.description.sponsorshipIDCNPq: 30182912008-0
dc.description.sponsorshipIDCNPq: 30771412006-3
dc.format.extent71-93
dc.identifierhttp://dx.doi.org/10.1586/ERI.09.108
dc.identifier.citationExpert Review of Anti-infective Therapy. London: Expert Reviews, v. 8, n. 1, p. 71-93, 2010.
dc.identifier.doi10.1586/ERI.09.108
dc.identifier.issn1478-7210
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/32162
dc.identifier.wosWOS:000273590700014
dc.language.isoeng
dc.publisherExpert Reviews
dc.relation.ispartofExpert Review of Anti-infective Therapy
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectbeta-lactamasesen
dc.subjectcarbapenemsen
dc.subjectefflux pumpsen
dc.subjectouter membrane proteinen
dc.subjectpolymyxinsen
dc.subjecttherapyen
dc.subjecttigecyclineen
dc.titleMultidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapyen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções
EPM - Outras produções